What top creators are saying about Eli Lilly and Company(LLY)— Page 2

Mentioned as an example of a healthcare company involved in changes associated with AI; no company-specific investment case was provided.

Eli Lilly was included in a speaker's hypothetical portfolio example focused on biotech and AI drug discovery. The 5x goal applied to the combined allocation and was not a forecast or guarantee.

A host named Eli Lilly as one way to express the biotechnology and AI drug-discovery theme. The 5x goal was personal, not a forecast or formal recommendation.

Named as part of broad support for pharmaceutical companies and vaccines, without stock-specific investment analysis.

Mentioned in a personal anecdote about tirzepatide and retatrutide, not as an investment thesis. No company outlook or recommendation was provided.

Named while the host expressed general support for pharmaceutical companies and vaccines, without company-specific analysis.

Mentioned in connection with AI-enabled drug discovery and Insilico Medicine; the theme was presented as a research opportunity rather than a specific recommendation.

The discussion estimated that roughly 70% of its enterprise value was tied to its GLP-1 drug family, highlighting both commercial importance and concentration risk.

Mentioned in market commentary without a developed investment thesis or price target.

Cited as a drugmaker that could face pricing pressure from government bargaining under a Medicare-for-All system; the discussion raised, but did not resolve, concerns about effects on pharmaceutical innovation.

A favorable Seventh Circuit decision on whether retatrutide qualifies as a biological product could extend patent protection and increase pricing power; the post characterizes that outcome as very bullish.

Investor interest is supported by momentum in GLP-1 drugs, but the cited $2,000 figure was an individual opinion without supporting valuation analysis.

The guest's largest stock position, Lilly is his strongest AI-related stock idea, with potential supported by GLP-1 demand and the intersection of AI and pharmaceuticals. Execution and possible safety or legal concerns are risks.

The speakers were bullish on tirzepatide’s potential, suggesting it could become one of the biggest drugs of all time and attract existing and new patients.

Patient interest in newer treatments could benefit Lilly, but the discussion offered no specific valuation view or recommendation.

Mando's favorite stock idea, based on GLP-1 medicines and broader health applications, with product-safety and legal concerns identified as risks.

Positioned as an AI agent beneficiary deploying capital to acquire biotech IP and partnering with AI platforms to accelerate discovery.

Positioned to unlock value from dormant IP by deploying multi-agent AI swarms to accelerate drug discovery pipelines.

Adopting frontier AI biological foundation models to scale virtual molecular screening, lower R&D failure rates, and shorten clinical development cycles.

Upcoming obesity drug retatrutide could generate billions as a blockbuster treatment, though microdosing trends, compounding alternatives, and generic competition present potential revenue friction.

Poised to benefit from broader addressable markets as the GLP-1 class expands into multi-indication preventative medicine and longevity applications beyond diabetes and weight management.

Positioned to benefit from an expanding GLP-1 addressable market that extends beyond weight loss and diabetes into broad preventative healthcare, multi-organ disease management, and longevity applications.

Experiencing recent sector-wide stagnation and trades at a 5x to 8x valuation premium relative to telehealth distribution partners.

Cited alongside other large equities as an example of fund managers publicly endorsing stocks aligned with their own investment exposure.

Included in a bullish long basket expected to resolve upward soon rather than consolidate

Target asset accumulated and airdropped to holders via the Peptides meme coin transaction fee mechanism.

Referenced in connection with the trending $PEPTIDES narrative within the meme meta.

Mentioned as a $1T market cap company connected to the biohacking peptides trend

Maintains a strong competitive pipeline in metabolic and anti-obesity drugs, notably with triple-agonist Retatrutide demonstrating approximately 33% weight reduction in Phase 3 trials.

Referenced as a $1.1 trillion market cap company providing narrative backing for the PEPTIDES token.

Gained +1.17% in a two-hour market recovery that is seen with caution as a potential bull trap.

Noted as a $1 trillion company benefiting from peptide interest and tied into a stock/meme coin meta, suggesting a big repricing is imminent.

Introduced Eblis for moderate-to-severe eczema, broadening its dermatology pipeline, though commercial uptake depends on efficacy against established competitors.

Solid long-term healthcare compounder being trimmed or exited by fund managers seeking higher-velocity, cyclical digital asset momentum.

Featured as a primary healthcare asset in the expansion of 24/7 tokenized real-world equity trading on Solana via platforms like Backpack.

Hitting all-time highs powered by massive cash flow from obesity drugs, which is being reinvested into AI-driven discovery and strategic M&A.

Scaling dedicated internal AI data centers to accelerate drug discovery pipelines, supporting strong top-line revenue expansion.

Positioned well in the next-generation metabolic pipeline with triple-hormone agonists like Retatrutide, which show potential in preserving lean muscle mass during rapid weight loss.

Expanded into Solana's tokenized equity market, enabling 24/7 trading, rapid settlement, and utility as on-chain DeFi collateral.

Offers less asymmetric upside in this cycle compared to smaller, data-rich biotech acquisition targets.

Demonstrates strong structural demand and defensive growth potential that historically outperforms tech during inflationary sector rotations.

Gained 3.3% to reach a new all-time high and a $1.2 trillion market cap on strong pharma sector momentum.

Investor reports significant short-term profits on long positions and anticipates the company reaching a $2T valuation after breaking all-time highs.

Reached fresh all-time highs above $1,278, advancing 4% to 5% amid strong macro rotation into healthcare.

Ebglus approval expands Lilly's footprint into the multibillion-dollar atopic dermatitis market, providing a key growth driver alongside its core diabetes and obesity franchises.

Features robust fundamental quality with ~50% YoY sales growth, a 32% return on invested capital, and minimal share dilution at a 25x forward P/E.

Bullish on LLY citing a $220k profit over the past week and a target of a $2T valuation.

Positioned as an application-layer beneficiary leveraging AI advancements.

Successfully beat earnings reports, viewed as a preferred angle for the AI trade, and has a specific price target of $5 trillion.

Eli Lilly demonstrated clear dominance in the diet drug wars, posting strong earnings and remaining the clear market leader in the GLP-1 weight-loss drug market.